SAGE Therapeutics (SAGE) Tops Q1 EPS by 9c

SAGE Therapeutics (NASDAQ: SAGE) reported Q1 EPS of ($1.52), $0.09 better than the analyst estimate of ($1.61).

Financial Guidance: Sage expects that its existing cash, cash equivalents and marketable securities will fund its anticipated level of operations, based on its current operating plans, into the second quarter of 2018.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c